Ketorolac eyedrops and ranibizumab combo reduces CMT

Article

A combination of ketorolac eyedrops 0.45% and intravitreal ranibizumab reduces central macular thickness (CMT) in choroidal neovascularisation (CNV), reveals a recent paper.

A combination of ketorolac eyedrops 0.45% and intravitreal ranibizumab reduces central macular thickness (CMT) in choroidal neovascularisation (CNV), reveals a recent paper.

Dr Andrea Russo et al., Department of Neurological and Vision Sciences, Eye Clinic, University of Brescia, Italy, conducted a pilot study on 56 patients who were randomized to receive the combination treatment (group 1) or ranibizumab alone (group 2).

All patients were administered monthly 0.5 mg ranibizumab injections for 3 months and in accordance with standard of care thereafter. Group 1 patients self-administered one drop of ketorolac three times a fay for six months and all patients underwent six months follow-up.

At the six-month follow-up both groups demonstrated a significant improvement in best-corrected visual acuity. The mean six-month change in CMT was −124 µm and −86.9 µm in groups 1 and 2, respectively. The combo group’s change in CMT was greater than the ranibizumab-only group. The combo treatment presented no adverse effects.

The combo treatment was found to be safe effective for reducing CMT. Topical ketorolac could actually supplement the activity of intravitreal ranibizumab in reducing CMT in CNV.

The abstract can be viewed in the British Journal of Ophthalmology.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.